drugset / Trial / NCT05211986
Safety and Tolerability of IMM01-STEM in Patients With Muscle Atrophy Related to Knee Osteoarthritis.
Non-randomizedSequentialOpen-labelTreatment
Summary
An open-label dose escalation study to assess the safety and tolerability of IMM01-STEM in participants with muscle atrophy related to knee osteoarthritis
Timeline
- Start
- 2022-09-13
- Primary completion
- 2026-03-30
- Completion
- 2026-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | IMM01-STEM | Unknown | 225 ug | Intramuscular |
| Comparator | IMM01-STEM | Unknown | 450 ug | Intramuscular |
| Comparator | IMM01-STEM | Unknown | 900 ug | Intramuscular |
| Comparator | IMM01-STEM | Unknown | 2000 ug | Intramuscular |